Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2021 Aug 12

PMID 34381332

Citations 8

Authors

Lijun Dai

Jiannan Wang

Mingyang He

Min Xiong

Ye Tian

Chaoyang Liu

Zhentao Zhang

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Pathologically, it is characterized by the aberrant aggregation of α-synuclein (α-syn) in neurons. Clinical evidence shows that patients with hypercholesterolemia are more likely to get PD, while lovastatin users have a lower risk of suffering from it. In this study, we investigated the effects of lovastatin on the aggregation and phosphorylation of α-syn . Our results demonstrate that α-syn preformed fibrils induce the phosphorylation and aggregation of α-syn in HEK293 cells stably transfected with α-syn-GFP and SH-SY5Y cells as well, which could be attenuated by in a concentration-dependent manner. Besides, lovastatin inhibited oxidative stress, histone acetylation, and the activation of casein kinase 2 (CK2). Collectively, lovastatin alleviates α-syn aggregation and phosphorylation in cellular models of synucleinopathy, indicating its potential value of being adopted in the management of PD.

Citing Articles

Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy.

Nohesara S, Mostafavi Abdolmaleky H, Thiagalingam S, Zhou J Epigenomics. 2023; 16(1):57-77.

PMID: 38088063 PMC: 10804213. DOI: 10.2217/epi-2023-0342.

The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease.

Battis K, Xiang W, Winkler J Int J Mol Sci. 2023; 24(17).

PMID: 37686080 PMC: 10487772. DOI: 10.3390/ijms241713270.

Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy.

Siwecka N, Saramowicz K, Galita G, Rozpedek-Kaminska W, Majsterek I Pharmaceutics. 2023; 15(8).

PMID: 37631265 PMC: 10459316. DOI: 10.3390/pharmaceutics15082051.

L116 Deletion in CSPα Promotes α-Synuclein Aggregation and Neurodegeneration.

Guo T, Xiong J, Feng H, Bu L, Xiao T, Zhou L Mol Neurobiol. 2023; 61(1):15-27.

PMID: 37566176 DOI: 10.1007/s12035-023-03552-z.

Monitoring α-synuclein Aggregation Induced by Preformed α-synuclein Fibrils in an Model System.

Kim B, Noh H, Jeon H, Park S Exp Neurobiol. 2023; 32(3):147-156.

PMID: 37403223 PMC: 10327928. DOI: 10.5607/en23007.

References

van der Most P, Dolga A, Nijholt I, Luiten P, Eisel U . Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009; 88(1):64-75. DOI: 10.1016/j.pneurobio.2009.02.002. View

. Burden of disease in Brazil, 1990-2016: a systematic subnational analysis for the Global Burden of Disease Study 2016. Lancet. 2018; 392(10149):760-775. PMC: 6123514. DOI: 10.1016/S0140-6736(18)31221-2. View

Luk K, Kehm V, Zhang B, OBrien P, Trojanowski J, Lee V . Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med. 2012; 209(5):975-86. PMC: 3348112. DOI: 10.1084/jem.20112457. View

Jensen E . Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken). 2013; 296(3):378-81. DOI: 10.1002/ar.22641. View

Kim S, Kwon S, Kam T, Panicker N, Karuppagounder S, Lee S . Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron. 2019; 103(4):627-641.e7. PMC: 6706297. DOI: 10.1016/j.neuron.2019.05.035. View

Homayoun H . Parkinson Disease. Ann Intern Med. 2018; 169(5):ITC33-ITC48. DOI: 10.7326/AITC201809040. View

Volpicelli-Daley L, Luk K, Lee V . Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc. 2014; 9(9):2135-46. PMC: 4372899. DOI: 10.1038/nprot.2014.143. View

Goers J, Manning-Bog A, McCormack A, Millett I, Doniach S, Di Monte D . Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry. 2003; 42(28):8465-71. DOI: 10.1021/bi0341152. View

. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16(11):877-897. PMC: 5641502. DOI: 10.1016/S1474-4422(17)30299-5. View

10.

Bar-On P, Crews L, Koob A, Mizuno H, Adame A, Spencer B . Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem. 2008; 105(5):1656-67. PMC: 2822545. DOI: 10.1111/j.1471-4159.2008.05254.x. View

11.

Park G, Tan J, Garcia G, Kang Y, Salvesen G, Zhang Z . Regulation of Histone Acetylation by Autophagy in Parkinson Disease. J Biol Chem. 2015; 291(7):3531-40. PMC: 4751393. DOI: 10.1074/jbc.M115.675488. View

12.

Koob A, Ubhi K, Paulsson J, Kelly J, Rockenstein E, Mante M . Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol. 2009; 221(2):267-74. PMC: 2812599. DOI: 10.1016/j.expneurol.2009.11.015. View

13.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

14.

Kaufman S, Sanders D, Thomas T, Ruchinskas A, Vaquer-Alicea J, Sharma A . Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron. 2016; 92(4):796-812. PMC: 5392364. DOI: 10.1016/j.neuron.2016.09.055. View

15.

Kawada T . Risk reduction of Parkinson disease by statin therapy in patients with diabetes. Ann Neurol. 2016; 81(1):157. DOI: 10.1002/ana.24809. View

16.

Monti B, Gatta V, Piretti F, Raffaelli S, Virgili M, Contestabile A . Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res. 2009; 17(2):130-41. DOI: 10.1007/s12640-009-9090-5. View

17.

Wahner A, Bronstein J, Bordelon Y, Ritz B . Statin use and the risk of Parkinson disease. Neurology. 2008; 70(16 Pt 2):1418-22. PMC: 3690297. DOI: 10.1212/01.wnl.0000286942.14552.51. View

18.

Lin K, Yang C, Lee M, Ho S, Liu C, Shin S . Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol. 2016; 80(4):532-40. DOI: 10.1002/ana.24751. View

19.

Holmes B, Furman J, Mahan T, Yamasaki T, Mirbaha H, Eades W . Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014; 111(41):E4376-85. PMC: 4205609. DOI: 10.1073/pnas.1411649111. View

20.

Luk K, Kehm V, Carroll J, Zhang B, OBrien P, Trojanowski J . Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338(6109):949-53. PMC: 3552321. DOI: 10.1126/science.1227157. View